Physician profile
Avan Jaff
NPI 1316406614
$2,013.06
in general payments reported to CMS, 2019-2025
32 companies · $655 in 2025
The $655 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.08 · 2022: $29.06 · 2023: $554 · 2024: $758 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $381.39 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $295.24 | 2022-2025 | |
| Abbott Laboratories | $154.69 | 2024-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $93.27 | 2023-2025 | Vyepti, Rexulti |
| Amgen INC. | $91.18 | 2023-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $80.47 | 2023-2024 | Farxiga |
| Dexcom, INC. | $76.41 | 2023-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $74.80 | 2023-2025 | Intellis Adaptivestim, Inceptiv, Minimed 780g |
| Shield Therapeutics INC | $67.36 | 2023-2024 | Accrufer |
| Astellas Pharma US INC | $62.22 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.62 | 2024-2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $53.09 | 2024 | Fanapt |
| Xeris Pharmaceuticals, INC. | $47.69 | 2023-2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.03 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $46.06 | 2024 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $40.08 | 2023 | |
| Inspire Medical Systems, INC. | $39.29 | 2025 | Inspire |
| Lilly USA, LLC | $32.45 | 2023-2024 | Mounjaro, Jardiance |
| Exact Sciences Corporation | $30.03 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $24.52 | 2024 | Injectafer |
| Antares Pharma, INC. | $20.99 | 2024 | Xyosted |
| Corcept Therapeutics | $20.95 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $20.91 | 2023 | Steglatro, Belsomra |
| Corium, LLC | $20.31 | 2023 | Adlarity |
| Nevro Corp. | $19.77 | 2023 | Senza |
| Globus Medical, INC. | $18.60 | 2025 | Senza |
| Boston Scientific Corporation | $18.58 | 2024 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $17.08 | 2023 | |
| Shire North American Group INC | $17.08 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.38 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $15.29 | 2023 | Shingrix, Arexvy |
| Abbvie INC. | $13.23 | 2023 | Qulipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avan Jaff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.